Treatment Of Subacute Thyroiditis Research Articles

Research Progress in the Treatment of Subacute Thyroiditis by Traditional Chinese Medicine

Subacute thyroiditis (SAT) is a self-limiting thyroid disease. At present, Western medicine mainly relies on the use of glucocorticoids and a variety of non-steroidal anti-inflammatory drugs in the treatment of SAT. Although the condition has been alleviated to a certain extent, its efficacy still needs to be further improved. Traditional Chinese medicine has unique advantages in the treatment of SAT. From the perspective of traditional Chinese medicine, this paper analyzed the understanding of traditional Chinese medicine in the etiology, pathogenesis and syndrome differentiation of SAT in recent years, and also reviewed the application of traditional Chinese medicine in the treatment of swelling with SAT, providing new insights and strategies for the clinical diagnosis and treatment of SAT.

Immature granulocytes and neutrophil-to-lymphocyte ratio as markers of treatment response in subacute thyroiditis.

Subacute thyroiditis is also known as subacute granulomatous thyroiditis, giant cell thyroiditis, painful thyroiditis, and De Quervain's thyroiditis. Immature granulocytes (IG) and neutrophil-to-lymphocyte ratio (NLR) are new inflammatory markers that are easily detected in routine complete blood count (CBC) tests. The aim of this study was to investigate the role of IG and NLR as markers of treatment response in patients with subacute thyroiditis. The study included 41 patients with subacute thyroiditis treated and monitored in our outpatient clinic between April 2020 and April 2022. From a retrospective review of medical records, we recorded results of IG, NLR, thyroid-stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) from blood tests obtained routinely before and after treatment. Overall, 31 (75.6%) patients were women and 10 (21.4%) were men. The median age was 41 years (range 22-68 years). The laboratory tests showed the following median (range) results: IG, 0.03 (0.01-0.08); NLR, 3.6 (1.2-5.2); TSH, 0.02 mIU/L (0.01-3.35 mIU/L); fT4, 2.3 ng/dL (1.0-7.0 ng/dL); fT3, 5.6 pmol/L (2.6-15.2 pmol/L); ESR, 49 mm/h (17.0-87 mm/h); and CRP, 73 mg/dL (3.0-188 mg/dL). Early diagnosis and treatment of subacute thyroiditis is fundamental. In the present study, the new inflammatory markers IG and NLR, measured routinely on CBC tests, decreased significantly after subacute thyroiditis treatment relative to pretreatment values. After treatment, the NLR change correlated with ESR and CRP changes, while the IG change correlated only with CRP change. These findings suggest that the markers IG and NLR may be used to evaluate treatment response in patients with subacute thyroiditis.

Diagnosis and Treatment of Subacute Thyroiditis

Diagnosis and Treatment of Subacute Thyroiditis

Comparison of the therapeutic effects of 15 mg and 30 mg initial daily prednisolone doses in patients with subacute thyroiditis: a multicenter, randomized, open-label, parallel-controlled trial

Introduction Current guidelines recommendations for the initial dose of prednisolone (PSL) in the treatment of subacute thyroiditis (SAT) are based on low-quality studies. We designed a randomized controlled trial (RCT) to compare the efficacy and safety of using a low initial dose of PSL with a standard initial dose of PSL in SAT patients. Patients and methods This open-label RCT was conducted at five hospitals in China from June 2019 to January 2022. SAT patients with moderate-to-severe pain or a poor response to non-steroidal anti-inflammatory drugs (NSAIDs) were randomly assigned in a 1:1 ratio to the experimental and control groups. The initial dose of PSL was 15 mg/d in the experimental group and 30 mg/d in the control group. The primary outcome was the total duration of PSL treatment, with non-inferiority prespecified with a margin of 7 days. Clinical trial registration number: ChiCTR1900023884. Results The full analysis set included 60 patients (30 in each group). The mean duration of PSL treatment in the experimental and control group was 34.62 ± 14.12 and 41.18 ± 16.89 days, respectively, meeting the non-inferiority criterion (pnon-inferiority = 0.0006). The total dose of PSL used in the experimental group was lower than in the control groups (330 vs 595 mg, p < 0.0001). There were no differences in the mean time to pain relief and complete resolution, the occurrence of recurrence, hypothyroidism, or adverse events between the groups. Conclusions The initial dose of 15 mg/d of PSL was not inferior to the dose of 30 mg/d in terms of efficacy and showed a similar safety profile. A low initial dose of PSL could be recommended for Chinese adult SAT patients who have a suboptimal response using NSAIDs or experience moderate-to-severe pain. KEY MESSAGES Low initial dose (15 mg/d) of prednisolone was non-inferior to the standard initial dose of prednisolone (30 mg/d) in treatment duration, time to pain relief, or the prevalence of hypothyroidism, recurrence, and adverse reactions in the treatment of subacute thyroiditis. Patients with subacute thyroiditis administered a low initial dose of prednisolone had a lower total dose of prednisolone compared to those receiving the standard dose of prednisolone.

THU656 Subacute Thyroiditis In Early Pregnancy: A Rare Case Report

Abstract Disclosure: F. El Sayed: None. D. Shelden: None. Background Subacute thyroiditis (SAT) is a self-limiting inflammatory disorder that can be caused by a viral infection and presents with neck pain, fever, and fatigue. To date, only 8 cases of SAT have been reported in pregnant women. Hyperthyroidism during pregnancy is associated with both maternal and neonatal complications. The early diagnosis and treatment of SAT during pregnancy may play a vital role in prevention of adverse fetal outcomes. Case Presentation A 37-year-old female in her 6th week was referred to the endocrinology clinic for neck pain that started two months ago following a viral sore throat. She also reported exhaustion, palpitations, and occasional dysphagia. This is her 10th pregnancy, and she reports a history of thyroid isthmic cysts with hemorrhagic degeneration drained in 2014.The patient is a former occasional smoker and denies alcohol or drug use. Family history is significant for autoimmune disease in her sibling, and type 2 diabetes mellitus in her father. On physical exam, her neck is soft, supple, with no lymphadenopathy. The thyroid gland is enlarged to approximately 40 grams and is mildly tender to palpation. Labs were significant for thyroid-stimulating hormone (TSH) of 0.01 uIU/ml (reference range 0.4-4.5 uIU/ml), serum-free triiodothyronine (FT3) of 4.7 pg/ml (reference rage 1.7-3.7 ng/dl), serum-free thyroxine (FT4) 1.6 pg/ml (reference range 0.7-1.5 pg/ml), ESR 67 mm/hr (reference range 0-18 mm/hr), CRP 52.6 mg/L(reference range &amp;lt;8 mg/L). Thyroid ultrasound revealed enlarged heterogeneous thyroid gland , with poorly defined hypoechoic areas. Based on patients’ symptoms, physical examination, and laboratory findings she was diagnosed with SAT. After review of prior literature and coordination with the patient’s obstetrician, she was started on prednisone 20 mg with a plan to taper by 5 mg weekly with close observation of thyroid function tests. Antibody assessment of thyroid was diffusely negative. Repeat assessment of the patient’s thyroid function tests showed improvement in tsh, FT3, and FT4 to 0.04, 2.4, and 0.9 respectively. The patient reported feeling significantly improved at the 2 week mark. Discussion and conclusion SAT during pregnancy is rare but requires careful management. To date, various treatment modalities are reported in case studies but there is a lack of consensus on medication dosing given the rarity of the presentation. The pathogenesis of SAT is still unknown but is thought to be secondary to destruction of thyroid follicular cells, resulting in the release of thyroid hormone and symptoms of thyrotoxicosis. SAT diagnosis is based on the patient's medical history, symptoms, physical and laboratory findings, and exclusion of other reasons for thyroid dysfunction. Pregnant women with hyperthyroidism need to be differentiated from Graves' disease, and monitoring of thyroid hormone levels is important for fetal outcomes. Presentation: Thursday, June 15, 2023

КЛИНИЧЕСКИЙ СЛУЧАЙ «ЛОНГ-КОВИДА» С ПОРАЖЕНИЕМ ЭНДОКРИННОЙ, СЕРДЕЧНО-СОСУДИСТОЙ И ЛЕГОЧНОЙ СИСТЕМ

Introduction. Coronavirus infection caused by the SARS-CoV-2 virus is characterized by a large range of clinical manifestations, which is associated with the presence of angiotensin-converting enzyme-2 receptors in many organs and tissues of the body. Subacute thyroiditis induced by COVID-19 is difficult to recognize due to the frequent absence of classical symptoms of thyroiditis. Aim. Demonstrate the features of the clinical course of a new coronavirus infection complicated by subacute thyroiditis and pericarditis in the distant period. Material and Methods. A clinical case of patient K., 56 years old, with damage to the pulmonary, cardiovascular and endocrine systems as a result of a new coronavirus infection was presented. Results and discussion. Subacute thyroiditis as a result of SARS-CoV-2 infection may have an atypical course. A pathognomonic feature of subacute thyroiditis is the high rate of erythrocyte sedimentation. The treatment of subacute thyroiditis in most cases requires the prescription of glucocorticoids. In some patients, prescribing nonsteroidal anti-inflammatory drugs may be sufficient to relieve symptoms. There was no clear association of cardiovascular symptoms in long-term COVID-19 with pre-existing cardiovascular pathology.. Conclusion. In the case of subacute thyroiditis developed as a result of SARS-CoV-2 infection, it is necessary to prescribe anti-inflammatory therapy in a timely manner. From a practical point of view, it is important to recognize cardiorespiratory symptoms in time as a non-specific manifestation of the long-term COVID-19 syndrome and the manifestation of cardiovascular pathology.

Subacute thyroiditis presenting as simple acute headache was misdiagnosed as meningitis: case report and literature review

BackgroundThe relationship between headache and thyrotoxicosis has been occasionally mentioned in case reports, but there are few related reports. Thus, the relationship cannot be determined. Few cases of subacute thyroiditis (SAT) presenting as simple headache have been reported.Case presentationThis case report describes a middle-aged male patient who came to our hospital with acute headache for 10 days. He was initially misdiagnosed as meningitis due to headache, fever, and increased C-reactive protein. Routine antibacterial and antiviral therapy did not improve his symptoms. Blood test suggested thyrotoxicosis, and color ultrasound suggested SAT sonography. He was diagnosed with SAT. With the treatment of SAT, the headache was relieved after the thyrotoxicosis improved.ConclusionThis patient is the first detailed report of SAT presenting with simple headache, which is helpful for clinicians to differentiate and diagnose atypical SAT.

Real-world effect of the treatment for painful subacute thyroiditis: The combined injection of lidocaine and triamcinolone using an insulin pen.

: Intrathyroidal injection using an insulin pen filled with a mixture of lidocaine and triamcinolone acetonide is a therapy for subacute thyroiditis (SAT) reported by us previously. We aimed to evaluate the clinical efficacy of ultrasound-guided intrathyroidal injection in the treatment of SAT. A total of 93 patients with SAT completed the study. All patients were evaluated via a history and clinical examination followed by thyroid function tests and ultrasonography of the thyroid. After ultrasound-guided intrathyroidal injection, the patients were followed up with respect to the injection frequency, treatment duration, and patient satisfaction. The visual numerical rating scale was used as a pain questionnaire for a given interval. Thyroid pain instantly decreased to scores below 3.0 following the first injection. Sixty-three patients (67.74%) avoided relapse of thyroid pain within 3 injections, which occurred within only 3 days after the first injection. The pain in 27 patients (29.03%) disappeared completely after 4-6 injections. Only 3 patients (3.23%) were found to need more than 6 injections, with 10 cited as the maximum number of injections, the injection took only 17 days altogether. The mean treatment cycle of the intrathyroidal injection was 3.98 days. There were no other associated complications with the novel therapy except infrequent small subcutaneous hematomas, which could be prevented with skilled practice. The average patient satisfaction score was as high as 9.0. Intrathyroidal injection of lidocaine and triamcinolone acetonide using an insulin pen was found to be an advantageous and satisfactory treatment for SAT.

Therapeutic implications in patients with subacute thyroiditis in the SARS-CoV-2 era

The purpose of this mini-review is to provide the latest information on the treatment of Subacute Thyroiditis (SAT) in the era of Coronavirus Disease 2019 (COVID-19). It is well documented that SAT has a significant impact on the quality of life of the patients, so early and proper diagnosis and treatment are necessary in order to reduce or even eliminate the severity of symptoms, frequency of relapses, and permanent hypothyroidism. This requires a multidisciplinary management approach in order to meet patients’ special needs. The present mini-review aims to summarize recent research evidence regarding the therapeutic management of SAT with special recommendations for COVID-19-associated SAT.

Effect Observation of Small-dose Glucocorticoid Combined with Indomethacin in the Treatment of Subacute Thyroiditis

Effect Observation of Small-dose Glucocorticoid Combined with Indomethacin in the Treatment of Subacute Thyroiditis

A systematic review and meta-analysis of the clinical efficacy and safety of Chinese patent medicines in treating subacute thyroiditis.

This meta-analysis was performed to evaluate the clinical efficacy and safety of Chinese patent medicines in the treatment of subacute thyroiditis (SAT). Chinese databases were searched using a combination of "patent Chinese medicine", "traditional Chinese medicine", "traditional Chinese and western medicine", "sub-thyroiditis", and "subacute thyroiditis". Studies that set Chinese patent medicine treatment of SAT as the experimental group were selected. Then, meta-analysis was performed by RevMan 5.3. A total of 12 studies were included, and most of them had a high risk of bias (low quality). The heterogeneity test results of clinical efficacy showed that Chi2=6.21, df=7, P=0.52>0.1, and I2=0%<50%. Then, the fixed effects model (FEM) was used, with OR =2.80; 95% confidence interval (CI): 1.89-4.13. The heterogeneity test of recurrence rate showed that Chi2=10.69, df=9, P=0.30>0.1, and I2=16%<50%. The heterogeneity test of erythrocyte sedimentation rate showed that I2=97%, P<0.00001, MD =-10.02; 95% CI: -12.88 to -7.16, and P<0.00001. The heterogeneity test of free triiodothyronine showed that Chi2=500.75, I2=99%>50%, P<0.00001, MD =-2.88; 95% CI: -3.85 to -1.91; Z=5.83, and P<0.00001. The heterogeneity test of free thyroid hormone showed that Chi2=25.15, I2=72%>50%, P=0.0007, MD =-2.48; 95% CI: -3.69 to -1.26; Z=3.99, and P<0.0001. The heterogeneity test of the occurrence of adverse reactions showed that Chi2=11.28, df=11, P=0.42>0.1, and I2=3%<50%, and the combined effect size was Z=6.49 and P<0.00001, with OR =0.21; 95% CI: 0.13-0.34. The meta-analysis of this study confirms that Chinese patent medicines have considerable clinical effects in the treatment of SAT. They can reduce the recurrence rate, adjust the levels of free triiodothyronine and free thyroid hormone, and have good safety.

The Evaluation of Low- and High-Dose Steroid Treatments in Subacute Thyroiditis: A Retrospective Observational Study

ObjectiveThe optimal steroid regimen in the treatment of subacute thyroiditis (SAT) is controversial. This study aims to compare low- and high-dose steroid regimens in the treatment of SAT. MethodsA single-center, retrospective observational cohort study with up to 1 year of follow-up was conducted. A total of 44 patients in the 16-mg methylprednisolone (MPS) group and 47 patients in the 48-mg MPS group were enrolled. Clinical and laboratory findings from the time of diagnosis to 1-year of the follow-up were assessed. Treatment response, recurrence, and hypothyroidism (HPT) rates were evaluated. ResultsClinical symptoms, sedimentation rates, C-reactive protein, and thyroid hormone levels of the patients were similar in the 2 groups. Recovery was achieved in all patients at the end of the treatments; however, treatment duration needed to be extended for 6 (13.6%) and 1 (2.1%) of the patients in the 16-mg and 48-mg MPS groups, respectively. The 48-mg MPS group had a higher SAT recurrence rate than the 16-mg MPS group (P = .04). Logistic regression analysis suggested that a lower thyroid-stimulating hormone level at the end of the treatment was a predictor of recurrence (β = –0.544, P = .014, 95% CI: 0.376-0.895). While the transient HPT rate was 10 (21.3%) and 10 (22.7%) in the 48-mg and 16-mg MPS groups, respectively, a permanent HPT developed in 5 (10.6%) of patients in the 48-mg MPS and 3 (6.8%) in the 16-mg MPS group. The permanent and transient HPT rates were determined to be similar in the low- and high-dose groups (P > .05). ConclusionLow-dose steroid therapy may be sufficient to achieve a complete recovery and better outcomes in SAT.

Analysis of the Molecular Mechanisms of the Effects of Prunella vulgaris against Subacute Thyroiditis Based on Network Pharmacology.

Prunella vulgaris (PV) has a long history of application in traditional Chinese and Western medicine as a remedy for the treatment of subacute thyroiditis (SAT). This study applied network pharmacology to elucidate the mechanism of the effects of PV against SAT. Components of the potential therapeutic targets of PV and SAT-related targets were retrieved from databases. To construct a protein-protein interaction (PPI) network, the intersection of SAT-related targets and PV-related targets was input into the STRING platform. Gene ontology (GO) analysis and KEGG pathway enrichment analysis were carried out using the DAVID database. Networks were constructed by Cytoscape for visualization. The results showed that a total of 11 compounds were identified according to the pharmacokinetic parameters of ADME. A total of 126 PV-related targets and 2207 SAT-related targets were collected, and 83 overlapping targets were subsequently obtained. The results of the KEGG pathway and compound-target-pathway (C-T-P) network analysis suggested that the anti-SAT effect of PV mainly occurs through quercetin, luteolin, kaempferol, and beta-sitosterol and is most closely associated with their regulation of inflammation and apoptosis by targeting the PIK3CG, MAPK1, MAPK14, TNF, and PTGS2 proteins and the PI3K-Akt and TNF signaling pathways. The study demonstrated that quercetin, luteolin, kaempferol, and beta-sitosterol in PV may play a major role in the treatment of SAT, which was associated with the regulation of inflammation and apoptosis, by targeting the PI3K-Akt and TNF signaling pathways.

Efficacy and safety of ultrasound-guided intrathyroidal injection of glucocorticoids versus routine oral administration of glucocorticoids for subacute thyroiditis: Protocol of systematic review and meta-analysis.

Background:This study was designed to systematically evaluate the clinical efficacy and safety of ultrasound-guided intrathyroidal injection of glucocorticoids (GCs) versus routine oral administration of GCs for subacute thyroiditis (SAT) and to help seek evidence of evidence-based medicine (EBM) for ultrasound-guided intrathyroidal injection of GCs in the treatment of SAT.Methods:Seven Chinese and English databases, including Chinese National Knowledge Infrastructure, Wanfang Data, VIP Information China Science and Technology Journal Database, SinoMed, PubMed, Cochrane Library, and Embase, were searched to collect randomized control trials on ultrasound-guided intrathyroidal injection of GCs in the treatment of SAT, which were published up to July 1, 2019. According to the method as described in Cochrane Reviewers’ Handbook 5.1.0, the Cochrane Collaboration's tool for assessing risk of bias was employed to evaluate the quality of the literatures included. Statistical analysis was made by using Stata 12.0. The “metanif” command was used for sensitivity analysis to assess the stability of the results. Funnel diagram method, Egger linear regression method, and clipping complement method were used to evaluate publication bias.Results:This study was carried out in strict accordance with the standard procedures for meta-analysis in the Cochrane Reviewers’ Handbook 5.1.0. Critical data about the primary and secondary outcome measures were obtained by statistical analysis.Conclusion:This study would draw a definite conclusion about whether ultrasound-guided intrathyroidal injection of GCs is effective and safe in the treatment of SAT on the basis of EBM. This conclusion would provide scientific evidence for the clinical treatment of SAT.

Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis.

The rate of recurrence of subacute thyroiditis (SAT) during prednisolone (PSL) therapy is approximately 10 to 20%. However, there is little or no information on the time period to relapse following administration of a tapered dose of PSL and the factors associated with such relapse. The aim of this study was to determine the correlation between SAT recurrence and PSL tapering regimen used in the treatment of SAT. This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT. The primary endpoint was the association between recurrence and number of days required to taper daily PSL dose to 5 mg. The secondary endpoint was the relationship between recurrence and several variables including age, clinical score, free thyroxine, inflammatory reaction, thyroglobulin, total treatment time, total dose of PSL and presence or absence of creeping thyroiditis. The SAT recurrence rate was 15.3%. There was no significant difference in the initial PSL dose between the non-recurrence and recurrence groups (27.5 mg vs 24.5 mg, P = 0.302). However, for the primary endpoint, significant differences were found between the two groups in time required for tapering PSL to 5 mg/day (non-recurrence: 44.3 ± 15.3 days, recurrence: 19.0 ± 11.9 days, P = 0.012). None of the clinical variables evaluated correlated significantly with SAT relapse. In conclusion, to prevent recurrence of SAT, consideration should be given to the period required for PSL tapering to 5 mg/day.

Chinese herbal medicine for subacute thyroiditis: a systematic review of randomized controlled trials

ObjectiveTo evaluate the effectiveness and safety of Chinese herbal medicine (CHM) in the treatment of subacute thyroiditis. MethodsRandomized controlled trials found in PubMed, Cochrane Library, and three Chinese databases were selected. RevMan 5.2 software was used to analyze the data with relative risk or mean difference, expressed with 95% of confidence interval. The quality of trials was assessed and graded the quality of evidence with GRADE profiler software. ResultsTwenty one studies were included. CHM was superior to Western Medicine (include prednisone and NSAIDs) in abating fever, relieving thyroid pain, recovering blood sedimentation, improving thyroid function, and preventing hypothyroidism (P<0.05), while no statistical differences were found in eliminating goiter and reducing relapse rate. CHM plus Western Medicine were superior to Western Medicine in abating fever, relieving thyroid pain, eliminating goiter, and reducing relapse rate, while no statistical differences (P>0.05) were found in recovering blood sedimentation and improving thyroid function. The incidence of adverse reactions in treatment group was lower than that in control group (relative risk was 0.12 and 95% confidence interval was 0.03-0.51). The methodological quality of trials is generally poor with a high risk of bias. ConclusionCHM (particularly CHM combined with Western Medicine) used to treat subacute thyroiditis may improve clinical symptoms and signs, reduce relapse rate, and alleviate the side effects of hormones. Due to poor methodological quality of included trials, further more high-quality studies are warranted to confirm the effectiveness and safety of CHM.

A Case of Deep Cervical Abscess during Treatment of Subacute Thyroiditis

Subacute thyroiditis is a nonsuppurative inflammatory disease whose treatment differs from that of acute suppurative thyroiditis. We report herein on a case diagnosed as subacute thyroiditis in which a deep cervical abscess developed as a result of overdosing with a steroid hormone agent. The patient was a 55-year-old male whose chief complaint was anterior neck swelling. Based on sonography findings and blood sampling results, a diagnosis of subacute thyroiditis was made and a steroid hormone agent was administered. Though the symptoms were initially relieved, when the drug was withdrawn, they worsened again. The patient himself was an internist and based on his own judgment increased the dosage of the steroid hormone agent. On the 14th day following the initial examination, he was reexamined due to worsening of the neck swelling and respiratory discomfort. CT showed that a deep cervical abscess had developed and an emergency surgical intervention was conducted to drain it. Thus, despite a diagnosis of subacute thyroiditis, the possibility of acute suppurative thyroiditis should be kept in mind and appropriate action taken in view of the clinical course.

Effect of operation in the treatment of subacute thyroiditis

Objective To explore the curative effects of operation in treatment of subacute thyroiditis.Methods The clinical data of 87 patients with subacute thyroiditis were retrospectively analyzed.According to the treatment methods,87 patients were divided into the operation group 39 cases and the medical treatment group(conservative group) 48 cases.Patients were followed up for 6 months after treatment.The clinical effect 1 week after the end of treatment was compared between the two groups.The thyroid functionat 6 months after the end of treatment was compared.Results The incidence rate of thyroid hyperfunction (hyperthyroidism) of the operation group was 33.33％,which was significantly higher than 8.33％ in conservative group,the difference was statistically significant (x2 =8.554,P =0.003).The effective rate of short-term treatment of operation group and the conservative group was 89.74％ and 93.75％,the difference was not significant (x2 =0.467,P =0.495).After 6 months of treatment,the normal rate of thyroid function between the two groups had no statistically significant difference(x2 =4.947,P =0.084).In the conservative group,3 cases were diagnosed as thyroid carcinoma complicated with hyperthyroidism.Conclusion For patients with refractory subacute thyroiditis or cannot exclude malignant tumors,operation can achieve good effect and less complications. Key words: Thyroiditis, subacute; Operation treatment; Curative effect

A Case of Deep Cervical Abscess during Treatment of Subacute Thyroiditis

A Case of Deep Cervical Abscess during Treatment of Subacute Thyroiditis

Clinical analysis of 45 cases with subacute thyroiditis

Objective To investigate the clinical manifestations,etiology,diagnosis and treatment of subacute thyroiditis(SAT).Methods Retrospectively analyzed 45 patients with subacute thyroiditis.Results In the cases 45with subacute thyroiditis,generallymore women who were 30～50 years old accounted for 88%.The clinical symptoms is typical,mainly headache(99%)and thyroid pain and obvious local tenderness(100%).45 patients were significandy higher erythrocyte sedimentation rate;d-2 cases of FT3,FT4 increased significantly,and the level of thyroid stimulating hormone is reduced.All patients of non-steroidal glucocorticoid treatment were effective.Conclusion The vast majority of subacute thyroiditis with typical clinical manifestations,the therapy of non-steroidal class and adrenal corticosteroid therapy is effective. Key words: Thyroiditis,subacute; Non-steroid; Glucocrticoids